Menu

Blog

Dec 12, 2023

FDA Weighs Gene-Editing Treatments’ Curative Possibilities Against Potential Risks

Posted by in categories: biotech/medical, genetics

As Vertex and CRISPR Therapeutics’ exa-cel and Verve Therapeutics’ VERVE-101 move forward, questions remain about possible drawbacks of such therapies.

Comments are closed.